Cargando…
Untargeted serum metabolomics reveals potential biomarkers and metabolic pathways associated with esophageal cancer
Metabolomics has been reported as an efficient tool to screen biomarkers that are related to esophageal cancer. However, the metabolic biomarkers identifying malignant degrees and therapeutic efficacy are still largely unknown in the disease. Here, GC-MS-based metabolomics was used to understand met...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513043/ https://www.ncbi.nlm.nih.gov/pubmed/36176418 http://dx.doi.org/10.3389/fonc.2022.938234 |
_version_ | 1784797967088091136 |
---|---|
author | Yang, Xiao-li Wang, Peng Ye, Hua Jiang, Ming Su, Yu-bin Peng, Xuan-xian Li, Hui Zhang, Jian-ying |
author_facet | Yang, Xiao-li Wang, Peng Ye, Hua Jiang, Ming Su, Yu-bin Peng, Xuan-xian Li, Hui Zhang, Jian-ying |
author_sort | Yang, Xiao-li |
collection | PubMed |
description | Metabolomics has been reported as an efficient tool to screen biomarkers that are related to esophageal cancer. However, the metabolic biomarkers identifying malignant degrees and therapeutic efficacy are still largely unknown in the disease. Here, GC-MS-based metabolomics was used to understand metabolic alteration in 137 serum specimens from patients with esophageal cancer, which is approximately two- to fivefold as many plasma specimens as the previous reports. The elevated amino acid metabolism is in sharp contrast to the reduced carbohydrate as a characteristic feature of esophageal cancer. Comparative metabolomics showed that most metabolic differences were determined between the early stage (0–II) and the late stage (III and IV) among the 0–IV stages of esophageal cancer and between patients who received treatment and those who did not receive treatment. Glycine, serine, and threonine metabolism and glycine were identified as the potentially overlapped metabolic pathway and metabolite, respectively, in both disease progress and treatment effect. Glycine, fructose, ornithine, and threonine can be a potential array for the evaluation of disease prognosis and therapy in esophageal cancer. These results highlight the means of identifying previously unknown biomarkers related to esophageal cancer by a metabolomics approach. |
format | Online Article Text |
id | pubmed-9513043 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95130432022-09-28 Untargeted serum metabolomics reveals potential biomarkers and metabolic pathways associated with esophageal cancer Yang, Xiao-li Wang, Peng Ye, Hua Jiang, Ming Su, Yu-bin Peng, Xuan-xian Li, Hui Zhang, Jian-ying Front Oncol Oncology Metabolomics has been reported as an efficient tool to screen biomarkers that are related to esophageal cancer. However, the metabolic biomarkers identifying malignant degrees and therapeutic efficacy are still largely unknown in the disease. Here, GC-MS-based metabolomics was used to understand metabolic alteration in 137 serum specimens from patients with esophageal cancer, which is approximately two- to fivefold as many plasma specimens as the previous reports. The elevated amino acid metabolism is in sharp contrast to the reduced carbohydrate as a characteristic feature of esophageal cancer. Comparative metabolomics showed that most metabolic differences were determined between the early stage (0–II) and the late stage (III and IV) among the 0–IV stages of esophageal cancer and between patients who received treatment and those who did not receive treatment. Glycine, serine, and threonine metabolism and glycine were identified as the potentially overlapped metabolic pathway and metabolite, respectively, in both disease progress and treatment effect. Glycine, fructose, ornithine, and threonine can be a potential array for the evaluation of disease prognosis and therapy in esophageal cancer. These results highlight the means of identifying previously unknown biomarkers related to esophageal cancer by a metabolomics approach. Frontiers Media S.A. 2022-09-13 /pmc/articles/PMC9513043/ /pubmed/36176418 http://dx.doi.org/10.3389/fonc.2022.938234 Text en Copyright © 2022 Yang, Wang, Ye, Jiang, Su, Peng, Li and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Yang, Xiao-li Wang, Peng Ye, Hua Jiang, Ming Su, Yu-bin Peng, Xuan-xian Li, Hui Zhang, Jian-ying Untargeted serum metabolomics reveals potential biomarkers and metabolic pathways associated with esophageal cancer |
title | Untargeted serum metabolomics reveals potential biomarkers and metabolic pathways associated with esophageal cancer |
title_full | Untargeted serum metabolomics reveals potential biomarkers and metabolic pathways associated with esophageal cancer |
title_fullStr | Untargeted serum metabolomics reveals potential biomarkers and metabolic pathways associated with esophageal cancer |
title_full_unstemmed | Untargeted serum metabolomics reveals potential biomarkers and metabolic pathways associated with esophageal cancer |
title_short | Untargeted serum metabolomics reveals potential biomarkers and metabolic pathways associated with esophageal cancer |
title_sort | untargeted serum metabolomics reveals potential biomarkers and metabolic pathways associated with esophageal cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513043/ https://www.ncbi.nlm.nih.gov/pubmed/36176418 http://dx.doi.org/10.3389/fonc.2022.938234 |
work_keys_str_mv | AT yangxiaoli untargetedserummetabolomicsrevealspotentialbiomarkersandmetabolicpathwaysassociatedwithesophagealcancer AT wangpeng untargetedserummetabolomicsrevealspotentialbiomarkersandmetabolicpathwaysassociatedwithesophagealcancer AT yehua untargetedserummetabolomicsrevealspotentialbiomarkersandmetabolicpathwaysassociatedwithesophagealcancer AT jiangming untargetedserummetabolomicsrevealspotentialbiomarkersandmetabolicpathwaysassociatedwithesophagealcancer AT suyubin untargetedserummetabolomicsrevealspotentialbiomarkersandmetabolicpathwaysassociatedwithesophagealcancer AT pengxuanxian untargetedserummetabolomicsrevealspotentialbiomarkersandmetabolicpathwaysassociatedwithesophagealcancer AT lihui untargetedserummetabolomicsrevealspotentialbiomarkersandmetabolicpathwaysassociatedwithesophagealcancer AT zhangjianying untargetedserummetabolomicsrevealspotentialbiomarkersandmetabolicpathwaysassociatedwithesophagealcancer |